07-Jan-2020 | Facts and Factors
Facts and Factors Market Research has published a new report titled “Plasmid Market By General Type (Conjugative and Non-Conjugative), by Specific Plasmid Types (F-Plasmids, Col Plasmids, Resistance Plasmids, Cryptic Plasmids, Degradative Plasmids, and Virulence Plasmids), and by Application (Transfection, Recombinant DNA Technology, Gene Therapy, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 – 2027”. According to the report, the global plasmid market is anticipated to be valued approximately USD 89 million in 2018 and is projected to hit the revenue of around USD 447 million by 2027, at a CAGR of around 19.5% between 2019 and 2027.
Plasmids are small circular double-stranded DNA molecules having the ability to duplicate independently. Moreover, the plasmid is different from chromosomal DNA and do not depend on chromosomal DNA for duplication. Plasmids are also referred to as replicons and they are the units of DNA that are capable of replicating independently within a suitable host.
Browse the full “Plasmid Market By General Type (Conjugative and Non-Conjugative), by Specific Plasmid Types (F-Plasmids, Col Plasmids, Resistance Plasmids, Cryptic Plasmids, Degradative Plasmids, and Virulence Plasmids), and by Application (Transfection, Recombinant DNA Technology, Gene Therapy, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 – 2027” Report at https://www.fnfresearch.com/plasmid-market-by-general-type-conjugative-and-non
Plasmids are primarily found in bacteria. However, they can also be detected in archaea and multicellular organisms. Plasmids generally carry minimum one gene. Most of the genes that plasmids carry benefit to host organisms.
Growing occurrence of cancer, genetic disorders, & contagious ailments to steer the market growth
Vectors are utilized in developing cancer treatments and this is likely to steer the growth of the plasmid market over the forecast timeline. In addition to this, continuous ongoing research targeting cancer and approvals of many of the biopharmaceutical medicines for treating cancer will impel the growth of the plasmid market over the forecast timeframe. Apart from this, the growing occurrence of chronic as well as contagious diseases producing escalating demand for improved therapies will proliferate the market scope over the forecast timespan.
Moreover, escalating awareness about the gene treatment along with the acceptance of gene therapy for treating ailments like Alzheimer and attention deficit hyperactivity will amplify the market growth over the forecast timeline. Apparently, gene therapy has a high potential for treating genetic disorders, as well as chronic ailments like cancer, will further enlarge the business growth over the forecast timespan. Nevertheless, mutagenesis coupled with huge costs related to gene therapy can act as a restraining factor for the plasmid industry over the forecast timeframe.
F-plasmids to dominate the specific plasmid types segment
F-plasmids segment is predicted to accrue a revenue of nearly USD 124 million by 2027. Some of the plasmids like F-plasmids possess the genes referred to as transfer genes enabling conjugation and this is likely to drive the expansion of the segment over the forecast timeline.
Gene therapy segment to contribute majorly towards the application landscape
The growth of the gene therapy segment is credited to a rise in the investment in research activities pertaining to gene treatment. Apart from this, increase in the awareness about the gene therapy, government support, and adoption of gene therapy for treating cancer will amplify the expansion of the gene therapy segment over the period from 2019 to 2027.
North America to dominate the overall regional market revenue share
North American market is likely to accrue a revenue of approximately USD 160 million by 2027. The growth of the market in the region is attributed to rising in the healthcare spending, approval of gene treatments for various chronic ailments, and rise in the investments in research activities pertaining to gene therapy applications in various domains.
Key players involved in the plasmid industry include Aldevron, GenScript, PlasmidFactory GmbH & Co. KG, VGXI, Inc., Oxford Genetics Ltd., Applied StemCell, Altogen Biosystems, Cobra Biologics, Copernicus Therapeutics, Inc., Takara Bio Inc., InvivoGen, Miltenyi Biotec, Medigene Sdn Bhd, MaxCyte, Inc., Mirus Bio LLC, MolMed S.p.A., GenePharma, and Polyplus Transfection.
This report segments the plasmid market as follows:
Global Plasmid Market: By General Type Segment Analysis
Global Plasmid Market: By Specific Plasmid Types Segment Analysis
- Col Plasmids
- Resistance Plasmids
- Cryptic Plasmids
- Degradative Plasmids
- Virulence Plasmids
Global Plasmid Market: By Application Segment Analysis
- Recombinant DNA Technology
- Gene Therapy
Global Plasmid Market: Regional Segment Analysis
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Facts & Factors
A 2108, Sargam,
Pune 411041, India